Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445961 | 0.88 | XDH (0.44) | XDHEPHX2NR1H4CSNK2A1EGLN1 | |
| SCHEMBL14049809 | 0.70 | EPHX2 (0.47) | XDHEPHX2NR1H4CSNK2A1EGLN1 | |
| SCHEMBL4443781 | 0.68 | HDAC2 (0.54) | EPHX2NR1H4HDAC1 | |
| SCHEMBL4441737 | 0.66 | ALDH1A1 (0.58) | — | |
| SCHEMBL1249264 | 0.66 | HIF1A (0.58) | XDHEPHX2NR1H4CSNK2A1 | |
| SCHEMBL4447240 | 0.65 | HPGD (0.43) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17132839 | 0.63 | MMP13 (0.68) | XDHEPHX2NR1H4KDM4C | |
| SCHEMBL30004856 | 0.63 | PFKFB3 (0.60) | XDHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2856871 | 0.63 | PFKFB3 (0.60) | XDHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4444275 | 0.63 | NPC1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008127364-A2 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | XDH 383/4885EPHX2 2642/4885NR1H4 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.